463 related articles for article (PubMed ID: 38211978)
1. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.
Mackintosh JA; Keir G; Troy LK; Holland AE; Grainge C; Chambers DC; Sandford D; Jo HE; Glaspole I; Wilsher M; Goh NSL; Reynolds PN; Chapman S; Mutsaers SE; de Boer S; Webster S; Moodley Y; Corte TJ
Respirology; 2024 Feb; 29(2):105-135. PubMed ID: 38211978
[TBL] [Abstract][Full Text] [Related]
2. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
5. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
Hilberg O; Simonsen U; du Bois R; Bendstrup E
Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Liu GY; Budinger GRS; Dematte JE
BMJ; 2022 Jun; 377():e066354. PubMed ID: 36946547
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis.
Molina-Molina M; Buendia-Roldan I; Castillo D; Caro F; Valenzuela C; Selman M
Arch Bronconeumol; 2022 May; 58(5):418-424. PubMed ID: 35312511
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Raghu G; Remy-Jardin M; Richeldi L; Thomson CC; Inoue Y; Johkoh T; Kreuter M; Lynch DA; Maher TM; Martinez FJ; Molina-Molina M; Myers JL; Nicholson AG; Ryerson CJ; Strek ME; Troy LK; Wijsenbeek M; Mammen MJ; Hossain T; Bissell BD; Herman DD; Hon SM; Kheir F; Khor YH; Macrea M; Antoniou KM; Bouros D; Buendia-Roldan I; Caro F; Crestani B; Ho L; Morisset J; Olson AL; Podolanczuk A; Poletti V; Selman M; Ewing T; Jones S; Knight SL; Ghazipura M; Wilson KC
Am J Respir Crit Care Med; 2022 May; 205(9):e18-e47. PubMed ID: 35486072
[No Abstract] [Full Text] [Related]
10. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
Collins BF; Raghu G
Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary.
Jo HE; Prasad JD; Troy LK; Mahar A; Bleasel J; Ellis SJ; Chambers DC; Holland AE; Lake FR; Keir G; Goh NS; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford HM; Chapman SA; Reynolds PN; Beatson D; Jones LJ; Hopkins P; Allan HM; Glaspole I; Corte TJ
Med J Aust; 2018 Feb; 208(2):82-88. PubMed ID: 29385965
[TBL] [Abstract][Full Text] [Related]
12. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
13. Developments in the management of idiopathic pulmonary fibrosis.
Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
[TBL] [Abstract][Full Text] [Related]
14. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
17. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
18. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
19. Management of Idiopathic Pulmonary Fibrosis.
Pleasants R; Tighe RM
Ann Pharmacother; 2019 Dec; 53(12):1238-1248. PubMed ID: 31280590
[No Abstract] [Full Text] [Related]
20. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ
Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
